Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatm... (een approved for the treatment of ALS. L...)

Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS

Date:10/15/2007

een approved for the treatment of ALS. Life expectancy after symptom onset is usually three to five years.

About Knopp Neurosciences Inc.

Knopp Neurosciences is a drug discovery and development company focused on delivering breakthrough treatments for neurological disorders through innovation, experience, and partnership. The company's lead product candidate is KNS-760704, an orally bioavailable small molecule in development for the treatment of ALS. Knopp's leadership includes experienced neuroscience drug development and discovery executives formerly associated with major pharmaceutical companies. Knopp's financing has been led by Saturn Capital Inc. of Boston as placement agent and Saturn Partners II as lead funder.

This press release contains "forward-looking statements," including statements relating to Knopp's planned regulatory filings and clinical development programs for KNS-760704. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that KNS-760704 will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market the products. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

0

GOOD

Page: 1 2
Related medicine technology :

1. Solstice Neurosciences Presents Escalating Dose Study at International Congress in Istanbul, Turkey
2. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
3. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
4. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
5. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
6. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
9. Point of Care Strep Tests Speed Treatment, Lower Costs
10. Rapid HIV Testing Increases Possibility of Treatment
11. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer

Post Your Comments:

Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatm...(een approved for the treatment of ALS. L...),Health